Bilateral synchronous breast cancer and HER-2/neu overexpression

Breast Cancer Research and Treatment

Volumn 72, Issue 3, 2002, Pages 195-201

  Safa, Malek ^a   Lower, Elyse E ^a   Hasselgren, P O ^b   Hungness, Eric S ^b   Gazder, Paula ^a   Aron, Bernard ^a   Shaughnessy, Elizabeth A ^b   Yassin, Rawia ^a  

^a UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

Bilateral; Breast cancer; Her 2 neu; Prognosis; Synchronous

Indexed keywords

NEU DIFFERENTIATION FACTOR;

ADULT; AGED; ARTICLE; BREAST CANCER; CONTROLLED STUDY; FEMALE; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; INVASIVE CARCINOMA; MAJOR CLINICAL STUDY; MORTALITY; ONCOGENE NEU; PRIORITY JOURNAL; PROGNOSIS; BREAST TUMOR; CANCER INVASION; GENE EXPRESSION REGULATION; GENETICS; LYMPH NODE METASTASIS; MIDDLE AGED; MULTIPLE CANCER; PATHOLOGY; PROTO ONCOGENE; RETROSPECTIVE STUDY; TIME;

AGED; BREAST NEOPLASMS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENES, ERBB-2; HUMANS; IMMUNOHISTOCHEMISTRY; LYMPHATIC METASTASIS; MIDDLE AGED; NEOPLASM INVASIVENESS; NEOPLASMS, MULTIPLE PRIMARY; RETROSPECTIVE STUDIES; TIME FACTORS;

EID: 0036010910     PISSN: 01676806     EISSN: None     Source Type: Journal    
DOI: 10.1023/A:1014958514851     Document Type: Article

References (30)

1. Bilateral primary breast cancer: A prospective study of disease incidence
2. Bilateral cancer of the breast: A review of clinical, histologic, and immunohistologic characteristics
3. Risk factors predicting the incidence of second primary breast cancer among women diagnosed with a first primary breast cancer
4. Bilateral breast cancer
5. Bilateral carcinoma of the breast
6. Occurrence and prognosis of contralateral carcinoma of the breast
7. Bilateral mastectomy for carcinoma of the breast
8. Radical excision of the chest wall for mammary cancer
9. Bilateral breast carcinoma: Results with breast conservation therapy and a comparison with bilateral mastectomy
10. Bilateral breast carcinoma treated with definitive irradiation
11. Early-stage bilateral breast cancer treated with breast-conserving surgery and definitive irradiation: The University of Pennsylvania experience
12. Analysis of cerbB2 expression using a panel of 6 commercially available antibodies
13. Plasma membrane phophotyrosine, Her-2/NEU, and epidermal growth factor receptor in human breast cancer
14. Bilateral synchronous breast cancer: Mode of detection and comparison of histologic features between the two breasts
15. Risk of subsequent contralateral breast carcinoma in a population of patients with in situ breast carcinoma
16. Bilateral breast cancer in patients with initial stage I and II disease
17. Bilateral breast carcinoma: Risk factors and outcomes for patients with synchronous and metachronous disease
18. Survival in bilateral breast cancer
19. Prognosis in bilateral breast cancer. Effects of time between first and second primary tumors
20. Efficacy of breast conservation therapy in early stage bilateral breast cancer
21. Simultaneous bilateral breast carcinomas: A retrospective review of 149 cases
22. NSABP investigators: Pathologic findings from the National Surgical Adjuvant Project (Protocol No 4). Bilateral breast cancer
23. HER-2/neu (c-erb-B2) gene and protein in breast cancer
24. Neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer
25. ERBB2 oncogene in human breast cancer and its clinical significance
26. A prospective study of the significance of gene and chromosome alterations as prognostic indicators of breast cancer patients with lymph node metastases
27. Predicting response to adjuvant and radiation therapy in patients with early stage breast carcinoma
28. Prognostic significance of c-erbB-2/neu amplification and epidermal growth factor receptor (EGFR) in primary breast cancer and their relation to estradiol receptor (ER) status
29. Prognosis of breast cancer: Evidence for interaction between c-erbB-2 overexpression and number of involved axillary lymph nodes
30. C-erbB2 overexpression decreases the benefit of adjuvant Tamoxifen in early-stage breast cancer without axillary lymph node metastases